The Food and Drug Administration has delayed reviews of two drugs selected for the Trump administration's fast-track approval program after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE